Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist. Berberine's blood sugar-lowering mechanism creates the same hypoglycemia concerns as with other GLP-1 medications.
Foundayo (orforglipron, oral)+Berberine
🔴
Major Interaction
Orforglipron + Berberine
Major interaction. Orforglipron and berberine both lower blood glucose — orforglipron via GLP-1 receptor activation, berberine via AMPK. Combined use significantly increases hypoglycemia risk. Do not combine without physician supervision.
What This Means
In Plain Language
The hypoglycemia risk from combining a GLP-1 receptor agonist with berberine applies to orforglipron just as it does to semaglutide and tirzepatide. Both substances independently lower blood glucose through different mechanisms, and their effects are additive. As an oral medication, orforglipron also shares GI side effects (nausea, diarrhea) with berberine, making compounded GI distress an additional concern.
Clinical Considerations
Key Risks & Factors
Additive hypoglycemia risk: GLP-1 receptor activation and AMPK-mediated glucose lowering are additive. This combination carries significant hypoglycemia risk, particularly for type 2 diabetes patients.
Compounded GI side effects: Both oral agents cause nausea and diarrhea. Combined use may significantly worsen GI side effects.
No clinical trial data: Orforglipron was approved in April 2026. No berberine interaction studies exist for this medication.
CYP3A4 consideration: Orforglipron is metabolized by CYP3A4. Berberine inhibits multiple CYP enzymes including CYP3A4, which could theoretically increase orforglipron blood levels and amplify both efficacy and side effects.
Conservative Safety Assessment
The combination of orforglipron and berberine carries the same Major interaction classification as berberine combined with other GLP-1 receptor agonists, with the additional consideration that berberine's CYP3A4 inhibition may affect orforglipron blood levels. Physician supervision, glucose monitoring, and patient education about hypoglycemia are required if concurrent use is considered. Reviewed and audited by Sanford A. Orloff, RPh (ret).
Enter all your medications, supplements, and lifestyle substances to see a complete pharmacist-reviewed interaction report — free, no account required.
Pharmacist-reviewed · FDA & NIH sources only · Always free
👨⚕️
Sanford A. Orloff, RPh (ret)
Registered Pharmacist · 40+ Years Clinical Experience · NPI 1518289974
Every interaction profile on InteractSafe is reviewed for editorial accuracy by a retired pharmacist with over 40 years of clinical experience in medication therapy management, patient counseling, and pharmaceutical care.
This combination is classified as a Major interaction. Both orforglipron and berberine lower blood sugar, creating additive hypoglycemia risk. Berberine may also affect orforglipron blood levels through CYP3A4 inhibition. Do not start berberine alongside orforglipron without explicit physician approval and glucose monitoring.
The hypoglycemia risk is similar across GLP-1 medications combined with berberine. Foundayo carries an additional consideration: as an oral small-molecule CYP3A4 substrate, berberine's CYP enzyme inhibition may increase orforglipron exposure. This is an additional reason for physician oversight with this combination.
This profile is for educational purposes only. Reviewed for editorial accuracy by Sanford A. Orloff, RPh (ret).
It is NOT medical advice and does not replace consultation with a licensed physician or pharmacist.
Never change your medication routine based on this information alone.
Read Full Safety Terms →